IPO

News

MapLight shares track up after $251m IPO

MapLight Therapeutics has made its debut on the Nasdaq, raising $251m for a lead drug that could be a rival to BMS' new schizophrenia drug Cobenfy.

News

Heather Turner, LB Pharma's chief executive.

After a long biotech IPO lull, LB Pharma chances its arm

After a promising start, IPOs all but fizzled out this year, but LB Pharma is hoping that won't stymy its chances of completing a Nasdaq listing.

News

Stada revives talk of an IPO – if conditions improve

Germany's Stada has said it may make another attempt to seek a public listing in the autumn, after delaying its plans earlier this year.

R&D

The sparkling opportunity of precision medicine represented by glittering DNA strand

Built for one: The case for custom formulation in the era of...

The precision medicine market is projected to exceed $175 billion by 2030, reflecting continued growth and interest in innovative approaches that tailor therapeutics that accounts for diffe

News

Caris swells its planned IPO, seeking $5.7bn valuation

AI-powered techbio firm Caris Life Sciences has raised the target price for its IPO, pointing to strong demand among investors.

News

Digital health firm Omada prices $150m IPO

In another sign of recovery in digital health investing, Omada Health has priced an IPO that could value the company at more than $1.1 billion.

MapLight shares track up after $251m IPO

After a long biotech IPO lull, LB Pharma chances its arm

Stada revives talk of an IPO – if conditions improve

Built for one: The case for custom formulation in the era of...

Caris swells its planned IPO, seeking $5.7bn valuation

Digital health firm Omada prices $150m IPO

LSX2026: On promise and patience, with Hans Schambye

Using AI-driven synthetic personas to take your insights fur...

IPO

Editor's Picks